Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.78, $0.19 better than the analyst estimate of $2.59. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $986.31 million.

GUIDANCE:

Charles River Laboratories sees FY2023 EPS of $9.90-$10.90, versus the consensus of $10.24.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.